InVision Precision Cardiac Amyloid
Adjunctive AI detection of cardiac amyloidosis — a rare, underdiagnosed, and now-treatable disease — from routine transthoracic echocardiography. Cleared as a diagnostic aid for adults aged 65 and older.
What it does.
Cardiac amyloidosis is a life-threatening, rare disease that is often misdiagnosed or underdiagnosed because its symptoms overlap with other causes of heart failure. With the emergence of disease-modifying therapies, timely and accurate detection has direct consequences for patient outcomes.
InVision Precision Cardiac Amyloid uses AI to evaluate features of cardiac amyloidosis across transthoracic echocardiogram studies containing apical-4-chamber and parasternal-long-axis view videos. Unlike single-view approaches, the algorithm integrates information across multiple standard echocardiographic views to assess amyloid-associated features holistically.
The underlying algorithm was peer-reviewed and published in JAMA Cardiology in 2022, previously received FDA Breakthrough Device Designation, and was enrolled in the FDA's Total Product Lifecycle Advisory Program (TAP). The American Medical Association has adopted CPT Category III code 0932T (effective January 1, 2025) for adjunctive technologies assisting clinicians in diagnosing and assessing patients with heart failure symptoms — providing a concrete reimbursement pathway. Development was supported by Alexion, AstraZeneca Rare Disease.
Peer-reviewed research behind the product.
Published in the peer-reviewed literature as EchoNet-LVH — the same model as InVision Precision Cardiac Amyloid. The literature uses the research name; the FDA clearance uses the product name. See every figure, including where we score lower →